

IN THE CLAIMS:

Please amend the claims as follows:

1. (Previously presented) A composition comprising a virus, said virus comprising a recombinant adeno-associated virus vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX and accompanying 5' and 3' untranslated regions and a transcription termination signal.
2. (Previously presented) The composition of claim 1, further comprising a portion of intron 1 of a Factor IX gene.
3. (Previously presented) The composition of claim 2, wherein said portion of intron 1 of a Factor IX gene is from about 0.3 kb to about 1.7 kb in length.
4. (Previously presented) The composition of claim 1, wherein said isolated DNA encoding Factor IX comprises a mutation which renders Factor IX encoded thereby incapable of binding to collagen IV.
5. (Previously presented) The composition of claim 4, wherein said mutation encodes an alanine residue in place of lysine in the fifth amino acid position from the beginning of mature F.IX.
6. (Previously presented) The composition of claim 1 further comprising a pharmaceutically acceptable carrier.
7. (Previously presented) The composition of claim 1, wherein said promoter/regulatory sequence is selected from the group consisting of the cytomegalovirus immediate early

promoter/enhancer, the skeletal muscle actin promoter and the muscle creatine kinase promoter/enhancer.

8. (Previously presented) The composition of claim 1, wherein said transcription termination signal is the SV40 transcription termination signal.
9. (Amended) A kit including the [vector] ~~virus~~ of claim 1, and instructions for using said kit.
21. (Previously presented) A composition comprising a recombinant adeno-associated virus vector comprising at least two adeno-associated virus inverted terminal repeats, a promoter/regulatory sequence, isolated DNA encoding Factor IX, wherein said isolated DNA encoding Factor IX comprises a mutation which renders Factor IX encoded thereby incapable of binding to collagen IV, and accompanying 5' and 3' untranslated regions and a transcription termination signal.
22. (Amended) The composition of claim ~~[[10]] 21~~, wherein said mutation encodes an alanine residue in place of lysine in the fifth amino acid position from the beginning of mature F.IX.
23. (Amended) The composition of claim ~~[[10]]-21~~, further comprising a portion of intron 1 of a Factor IX gene.
24. (Amended) The composition of claim ~~[[12]] 23~~, wherein said portion of intron 1 of a Factor IX gene is from about 0.3 kb to about 1.7 kb in length.
25. (Amended) The composition of claim ~~[[1]]-21~~ further comprising a pharmaceutically acceptable carrier.

26. (Amended) The composition of claim [[1]]-21, wherein said promoter/regulatory sequence is selected from the group consisting of the cytomegalovirus immediate early promoter/enhancer, the skeletal muscle actin promoter and the muscle creatine kinase promoter/enhancer.
27. (Amended) The composition of claim [[1]] 21, wherein said transcription termination signal is the SV40 transcription termination signal.
28. (Amended) A kit including the vector of claim [[1]] 21, and instructions for using said kit.

#### REMARKS

These remarks are in response to the Office Action mailed February 24, 2003. Claims 1 to 9 and 21 to 28 are pending. Claims 10 to 17, filed in Applicants November 19, 2002, Response have been renumbered by the Examiner as claims 21 to 28, which is reflected by the present amendment. Thus, claims 1 to 9 and 21 to 28 are under examination. Applicants respectfully request re-consideration of the application.

#### Regarding the Amendments

The amendments were made in order to address several informalities. In particular, the amendment to claim 1 to recite "virus," was made in view of the amendment to claim 1 in Applicants November 19, 2002, Response. The amendments to claims 22 to 24 to depend from claims 21 and 23 were made in light of the renumbering of these claims. The amendments to claims 25 to 28 to depend from claim 21 instead of claim 1 were made to provide the correct claim dependency. Thus, as the claim amendments were made to address several informalities, no new matter has been added and entry thereof is respectfully requested.